Important Safety Information Prescribing Information Patient Site Request an Account Manager
Eye care professional with patient

The numbers
are in focus

Qlosi delivers clear near vision
without compromising distance vision1,2
Clara T.
“
Let’s bring it into focus”

~8 out of 10 patients.

Day or night. Up to 8 hours1,3

20/40 or better near vision, day or night2*

Day 15: Participants with DCNVA 20/40 or better in binocular vision,
excluded participants with baseline 20/40 or better OU DCNVA.3
Line chart: percentage of participants with 20/40 or better DCNVA by hour after dose, Day 15 — more than 8 out of 10 patients

*Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.1

DCNVA=distance-corrected near visual acuity; OU=oculus uterque

What ECPs see in practice

“
The feedback we’ve been receiving is quite positive. From folks working at computer screens for hours–they feel relief and lack of strain at the end of the day. To folks looking at their phones seeing that benefit as well.”

→ Dr. Kevin Gee, OD Missouri City, TX

Dr. Kevin Gee
“
Me personally using Qlosi, it made it harder to go back to my multifocal contacts. I see great up close, but my distance is perfect.”

→ Dr. Brian Brightman, OD Lincoln, NE

Dr. Brian Brightman
“
I’ve enjoyed the freedom from glasses and contacts all my life and to now push up against certain activities up close. Qlosi has helped me extend that freedom.”

→ Dr. Jonathan Solomon, MD Chevy Chase, MD

Dr. Jonathan Solomon

Patients say it best

“
I just couldn’t believe how everything appeared so much brighter and sharper. I could see it [nearly] immediately. Tennis is number one: everything is sharper and brighter.”

→ Joelle Hamontree, Patient

Joelle Hamontree
“
Being able to see unit marks on my syringes when I’m injecting somebody. I’m able to just have a straight conversation with somebody and not feel obligated to have to put glasses on. It has been absolutely life-changing.”

→ Suzanne Chick, Patient & Nurse Practitioner

Suzanne Chick

Fast onset. Real world.

Near vision improvement seen as early as 20 minutes.*
Best results with consistent use over 2 weeks2
Qlosi carton and vial

Not actual size

Use daily or as needed, on the patient’s schedule.

*Measured on Day 15 of clinical studies.

See full safety profile → See how to prescribe Qlosi →

Indication and Usage

Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

Important Safety Information

Contraindications

Hypersensitivity

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

Qlosi is not recommended to be used when iritis is present.

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the instillation of Qlosi and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

Please see full Prescribing Information here: qlosiecp.com/prescribing-information

References

  1. Qlosi [package insert]. Ponte Vedra, FL. Orasis Pharmaceuticals.
  2. Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  3. Cunningham D, Koetting C, Lang J. Comparison of monocular and binocular near vision improvement in the NEAR-1 and NEAR-2 phase 3 randomized, clinical trials: CSF-1 (0.4% pilocarpine HCl) for the treatment for presbyopia. Poster presented at AOA Optometry Meeting; June 21-23, 2024; Washington, DC.